ALOFT-IPF IM027-068: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis.
To evaluate the efficacy of 2 doses of BMS-986278, 60 and 120 mg BID, compared with PBO, in demonstrating improvement in absolute change in FVC from baseline at Week 52
Study details
Study-ID: 2023-503697-21-00
Study-ID: 2023-503697-21-00
DZL Disease Area: DPLD
DZL Disease Area: DPLD
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center
DZL Role: DZL recruiting center
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: CPC-M
DZL Participating Sites: CPC-M
Start Date: 01.10.2024
Completion Date: 31.12.2025
Status: Recruiting
Status: Recruiting
DZL recruiting center
Disease: Participants with Idiopathic Pulmonary Fibrosis
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
